Rosa to Present at 2012 Keystone Symposia: Advances in Islet Biology

Modeling analysis enables development of biomarkers for beta cell mass.

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent research project will be presented at the 2012 Keystone Symposia: " Advances in Islet Biology " in Monterey, California on March 28, 2012. Dr. Mike Reed will be presenting a poster entitled "Non-invasive prediction of beta cell mass in type 2 diabetes: insights from a mathematical model". The poster describes the development of an improved approach to develop and validate biomarkers of pancreatic beta cell mass. Beta cell mass is a critical component in the pathophysiology of type 2 diabetes, but accurate clinical measurements for are not currently feasible. The main benefit of this research is that it enables the development of predictive, clinically measureable markers for beta cell mass. This work will also highlight the use of a Diabetes PhysioPD™ model to gain additional insight into the impact of changes in beta cell mass on diabetes outcomes and standard clinical measures of beta cell function.

"This work supports fundamental insights into beta cell dynamics in type 2 diabetes, patient variability, and the response to beta cell-modifying therapies," said Dr. Rebecca Baillie, Rosa's Chief Scientist. "With many diabetes therapies in development which target beta cell regeneration, it has become critical to have accurate measures of beta cell mass. This research will enable the identification of predictive clinical markers.

Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.